GLP-1 Dosing Schedules: Titration, Missed Doses, Restart

Why GLP-1 medications are titrated

Starting a GLP-1 medication at full dose would not work for most people. The gastrointestinal side effects scale with dose, and the body needs time to adapt to slowed gastric emptying. Every prescribing label for these drugs builds in a stepwise titration: a low starting dose for the first month, then incremental increases until either the target maintenance dose is reached or side effects dictate holding at a lower step.

The point of titration is not just tolerability. The lower steps are not therapeutic doses for weight management; they are runway. The clinically meaningful effect on weight tends to emerge once a patient reaches the higher maintenance doses and stays there for several months.

The standard pattern

The exact steps differ by product but the overall shape is the same. Semaglutide for weight management starts at a low weekly dose for four weeks, then increases roughly every four weeks through several intermediate steps before reaching the maintenance dose. Tirzepatide follows a similar four-weeks-per-step pattern with its own dose ladder. The injectable products are weekly; oral semaglutide is daily and has its own titration.

The standard guidance from prescribing information is to stay at each step for at least four weeks before moving up. Some patients move faster, some slower. The pace is driven by side-effect tolerability, not the calendar. A patient still vomiting at week three has no business stepping up at week four.

Plateauing at a step

There is no single rule for when to step up versus stay. The framing most clinicians use is: if a patient is tolerating the current dose well and weight loss is on track, step up at the scheduled interval; if side effects are still meaningful, hold the current dose for another four weeks before considering the next step; if side effects are severe or weight loss is rapid enough that further escalation seems unnecessary, the current step can become the long-term maintenance dose. Many patients reach a satisfactory result without ever reaching the maximum approved dose.

What "maintenance" means

Maintenance is the dose a patient stays on indefinitely once titration is complete. For weight management indications, the maintenance dose is the highest tolerated step that produces continued benefit. There is no requirement to reach the maximum approved dose; the labeled maximum is the ceiling, not the target.

The published trial data show that weight loss generally continues for about 60 to 68 weeks before flattening. Once a plateau is reached, the medication is usually continued at the same dose to maintain the loss rather than escalated further.

Missed doses

Each product specifies what to do with a missed weekly dose. The general structure is: if the missed dose is within a defined window from the scheduled day, take it as soon as possible and resume the regular weekly schedule; if more than the defined window has passed, skip the missed dose and take the next one on the scheduled day. Do not double up.

A missed week is not catastrophic. A pattern of irregular dosing, however, defeats the purpose of the titration. The steady weekly cadence is what allows the body to adapt and what produces the consistent appetite signaling these medications are designed to provide. If life circumstances make a weekly schedule difficult, a fixed anchor (Sunday morning, Wednesday evening, whatever works) makes adherence dramatically easier than trying to remember each week.

Stepping down or stopping

There is no medical requirement to taper a GLP-1 medication on the way off, the way one might taper a glucocorticoid. Patients can stop at any time. The practical concern is rebound: weight loss without sustained behavioral change tends to reverse once the medication is stopped, and appetite returns to baseline within weeks. The published data on semaglutide and tirzepatide both show meaningful weight regain over the year following discontinuation in most patients.

Some patients choose to maintain on a lower dose long-term as a compromise between cost or side effects and continued benefit. That is a conversation with the prescriber and not something to attempt by reducing dose ad hoc.

Restarting after a gap

A multi-week gap in dosing changes the picture. The body re-sensitizes during the gap, and resuming at the previous maintenance dose can re-trigger the full intensity of early side effects. Many prescribers recommend restarting at a lower step and titrating back up rather than resuming at the prior maintenance dose. The longer the gap, the further down the ladder the restart should be.

When to seek medical advice

Talk to the prescriber before changing any aspect of the dosing schedule. Persistent inability to tolerate even the starting dose, sustained weight loss faster than roughly two percent per week, severe abdominal pain, or signs of dehydration are reasons to pause and reassess rather than push through. Hypoglycemia is uncommon on GLP-1 monotherapy but possible when combined with insulin or sulfonylureas, and adjustments to those other medications may be needed as the GLP-1 dose escalates.

---

Wegovy®, Ozempic®, Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro®, Zepbound® are trademarks of Eli Lilly and Company. PepAI is independent.